16/01/2020 - Institutional news
The global organisation Worldwide Cancer Research, based in Scotland, will fund a three-year breast cancer metastasis study by Toni Celià-Terrassa, from the IMIM's Molecular Cancer Therapy Research Group. The project aims to explore the dynamics and behaviour of tumour populations that undergo epithelial-mesenchymal transition (EMT) during breast cancer metastasis. For this purpose, advanced 3D microscopy and single-cell transcriptomic techniques will be used in conjunction with computational biology analysis.
Més informació "Worldwide Cancer Research sponsors a breast cancer metastasis project at the IMIM"
23/08/2019 - Press release
Researchers from the Molecular Cancer group at the Hospital del Mar Medical Research Institute (IMIM) and doctors from Hospital del Mar, have demonstrated the effectiveness of a drug for treating metastatic bladder cancer in patients who did not respond to the usual treatment. The preliminary results of an ongoing clinical trial show that TAK-228, a mTORC1/2 protein inhibitor, can stop the progression of the disease. Four of the seven patients in the trial showed positive results. The trial also involved Hospital de la Santa Creu i Sant Pau in Barcelona, Hospital Universitari Parc Taulí in Sabadell, Clínica Universitaria in Navarre, and Hospital General Universitario in Elche.
Més informació "Effectiveness of a new bladder cancer treatment demonstrated"
10/07/2019 - Press release
A study led by researchers from the Hospital del Mar Medical Research Institute (IMIM), has determined, for the first time, the importance of a cell mechanism that may be key to treating metastatic tumours. The work has demonstrated the role a protein, kinase IKKα, plays in the ability of tumour cells to repair themselves. This is a key factor in treatment resistance and tumour spread. The research has been published in the journal Molecular Cell. The researchers analysed the role of this protein, activated by mutations of the BRAF and KRAS oncogenes, present in the majority of the most aggressive tumours. The function of this protein is to facilitate DNA-repair in tumour cells after they have been damaged by chemotherapy, making them more resistant to the action of these drugs. This is key for the treatment approach, since this new study demonstrates, conclusively, that combining a BRAF oncogene inhibitor with chemotherapy deactivates and kills the tumour.
Més informació "Mechanism determined for treating the most aggressive tumours"
29/10/2018 - Press release
The study, published in the journal Cancer Research, shows the pivotal role of the enzyme USP27X in the control of the proliferation, invasion and formation of breast cancer metastasis and opens new pathways to the development of anti-tumour drugs. A team of researchers from the Cancer programme of the Hospital del Mar Medical Research Institute (IMIM), led by Drs Victor M. Diaz, of Pompeu Fabra University (UPF) and Antonio García de Herreros, of the IMIM, has identified a key enzyme in cancer development called USP27X.
Més informació "Discovery of a key protein in tumour metastasis"
02/08/2018 - Press release
Inhibiting the Jagged 1 protein in mice prevents the proliferation and growth of colon and rectal tumours. What is more, this approach to the disease permits the removal of existing tumours. This is the conclusion of a study led by the Molecular Mechanisms of Cancer and Stem Cells research group from the Hospital del Mar Medical Research Institute (IMIM), directed by Dr Lluís Espinosa, who is also a member of CIBERONC (the Network Centre for Biomedical Research into Cancer), in collaboration with the Pathological Anatomy and Medical Oncology Units at Hospital del Mar, and the IDIBELL-Catalan Oncology Institute. The work has been published in Nature Communications. The researchers took tumours from patients and then implanted them into mice in order to analyse the role of this protein in cancer cell proliferation. Jagged 1 is essential for cancer cells due to its role in activating the so-called Notch cell-signalling pathway. Generally speaking, Notch inhibits cell differentiation, in other words, a cell's ability to become a mature cell that can no longer proliferate. In the case of colorectal tumours, the activation of this signalling pathway favours their proliferation and growth.
Més informació "Key piece identified for slowing a colorectal cancer subtype"
17/05/2018 - Institutional news
The two IMIM researchers, Lluís Espinosa and Anna Vert, have been chosen to edit a special edition of the journal Biomedicines, from the MDPI publishing house. Under the title Stem Cells and Cancer Therapeutics, it will focus, in the words of the publishers, "on understanding the molecular mechanisms controlling normal cells and stem cells related to cancer, as well as the tools available for studying them in vitro and in vivo." This issue will focus on how new technologies can be used in cancer therapies. The special edition will include around twelve articles by particularly renowned authors. Five of these articles can already be consulted in open format, including the paper "Mammary Stem Cells and Breast Cancer Stem Cells: Molecular Connections and Clinical Implications", authored by Dr. Toni Celià-Terrassa, a researcher from the IMIM's Cancer Research Programme.
03/11/2017 - Press release
Dr. Joaquim Bellmunt, director of the Hospital del Mar Medical Research Institute (IMIM) and Associate Professor at the University of Harvard, at Dana Farber Cancer Institute in Boston, is one of the first authors of a new international study that has mapped genome of bladder cancer. As part of the TCGA project (The Cancer Genome Atlas), the researchers have reported their final analysis of 412 tumour samples, providing the most accurate genetic description to date of this type of cancer. This will enable the analysis of new personalised treatment hypotheses for this disease. The study was published in the journal Cell. Dr. Bellmunt has stated that thanks to this work, we now "have a much broader perspective on the different varieties of urinary bladder cancer and its genetic alterations". Even so, the head of the IMIM stresses that "it is necessary to continue researching the best treatments and confirm hypothesised new treatment methods."
20/02/2017 - Press release
An international multicentre study led by cancer specialist Joaquim Bellmunt, director of the Hospital del Mar Medical Research Institute (IMIM) and coordinator of the IMIM's Genitourinary Oncology research group, has demonstrated the effectiveness of immunotherapy in treating advanced bladder cancer when the initial chemotherapy using cisplatin no longer works. It is the first time patient survival has been significantly prolonged in this kind of situation. The treatment also improves the quality of life of patients with respect to chemotherapy. This phase III study published in the highly prestigious New England Journal of Medicine, a benchmark for advances in applied medicine, becomes a reference work as until now there had been no significant breakthroughs in bladder cancer treatment that could be applied when the first option was no longer effective. These results provide evidence supporting the use of Pembrolizumab, an immunotherapy drug, as a new standard treatment for advanced bladder cancer, as has also been demonstrated for other types of tumour such as melanoma and lung cáncer.
26/04/2016 - Press release
The expansion of the genetic test allows the detection of newly identified mutations by a team of oncologists at Hospital del Mar and the IMIM that explain a further 10-15% of the resistance to a group of drugs developed by colorectal tumours The resistance caused by EGFR mutations described by the same team of oncologist has been shown to be important in more of 25% of the patients treated using anti-EGFR therapy This work is a clear example of how in just a short time the results of a research project have been transferred to industry, in this case the Belgian multinational Biocartis, and how they have an almost immediate application in patients, improving and personalising colon cancer treatments The patent for the first test was obtained in 2013, the detection kit was marketed in 2014, and it has now been expanded, with a new licence, to include the newly-detected mutations
08/02/2016 - Institutional news
On February 4, to coincide with World Cancer Day, the AECC-Catalunya contra el Càncer, presented their Cancer Research Grants 2015 at the Drassanes Reials in Barcelona, in a ceremony attended by more than 400 people from the worlds of politics and business, as well as the general public. In this edition the AECC presented a total of €120,000 to six projects by emerging Catalan teams looking at colon cancer, leukaemia, brain tumours, gastrointestinal stromal tumours and prostate and bladder cancer. The winners include a project entitled: “Clinical implications of galectin-1 expression in genitourinary cancer: its role in diagnosis, prognosis and response prediction with immune check point inhibitors”, led by Pilar Navarro, coordinator of the Molecular Mechanisms of Tumorigenesis research group at the IMIM and Alejo Rodríguez-Vida, an oncologist at the Hospital del Mar
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
